Proteocyte AI

Home
Canada
Toronto, ON
Proteocyte AI

Directions Website

A Canadian molecular diagnostics company with a novel technology that determines the risk of a head

Better cancer diagnostics

Our novel diagnostic technology, Straticyte™, determines the risk of a head and neck lesion becoming cancerous in the near future. If the risk is high, clinicians can provide early interventions. Clinicians can follow-up effectively with moderate and low risk lesions. Accurate early diagnosis and treatment will drastically improve the clinical outcomes and quality of life for people with head and neck cancer.

11/05/2026

November is Mouth Cancer Action Month — a time to raise awareness, recognize the signs, and highlight the importance of early detection, early prediction and early management.

Mouth cancer can affect the lips, tongue, gums, cheeks, and other areas of the oral cavity. Changes in the mouth can sometimes go unnoticed, making regular dental checkups and timely evaluation of persistent or unusual lesions essential.

At Proteocyte AI, we’re working to advance oral cancer risk prediction with STRATICYTE®, a prognostic test that uses biomarker analysis and advanced digital pathology to provide a personalized 5-year oral cancer risk score from an existing biopsy.

Because understanding risk can help inform conversations about monitoring, intervention, and next steps in care.

Know the signs. Understand the risk. Take action.

Learn more about STRATICYTE®: https://proteocyte.com/straticyte/

Seattle Jaw Surgery Society of OMS Administrators SPOHNC Mouth Cancer Foundation Oral Health Foundation SurgeOn Events

11/03/2026

A pathology report on your biopsy can provide important answers—but you may still have questions about what comes next.

The STRATICYTE® test uses your existing biopsy to provide a personalized 5-year oral cancer risk assessment, helping your healthcare provider better understand your risk and guide your care.

✔ No additional biopsy required
✔ Personalized to your risk
✔ Supports more informed care decisions
Know your risk. Understand your options.

Ask your healthcare provider about STRATICYTE®:
👉 https://proteocyte.com/straticyte/patients/

American Dental Association Beacon Oral & Maxillofacial Surgeons Everyday Oral Surgery Head and Neck Cancer Alliance Osteo Science Foundation Oral Cancer Foundation Paradigm Oral Health

10/29/2026

Don’t Let Oral Cancer Risk Haunt You. 👻

Not every oral lesion carries the same risk—and some may have no symptoms at all.

STRATICYTE® provides a personalized 5-year oral cancer risk score using your existing biopsy tissue.

Don’t leave risk to guesswork.
Spot it. Test it. Know your risk.

👉 Learn more: https://proteocyte.com/straticyte/patients/

American Academy of Otolaryngology—Head and Neck Surgery American Academy of Oral Medicine American Academy of Oral and Maxillofacial Pathology - AAOMP American Association of Oral and Maxillofacial Surgeons - AAOMS American Cancer Society

10/22/2026

Who Is Most at Risk?

Managing OPMDs requires understanding not just what a lesion is—but how likely it is to progress.

STRATICYTE® supplements conventional histopathology with biomarker analysis and digital pathology to provide a personalized 5-year oral cancer risk score.

Use deeper insight to support:
✔️ Surveillance
✔️ Intervention
✔️ Treatment planning

Predict Oral Cancer Risk with STRATICYTE®.
👉 https://proteocyte.com/straticyte/

Nova Scotia Dental Association Ontario Dental Association Ontario Society of Oral and Maxillofacial Surgery The Terry Fox Foundation The Princess Margaret Cancer Foundation

10/20/2026

Not All Lesions Carry the Same Risk.

Some oral potentially malignant disorders may progress to cancer, while others may not.

STRATICYTE® goes beyond traditional pathology to provide an objective, personalized assessment of your 5-year oral cancer risk.

More insight can mean more informed decisions.

Ask your healthcare provider about STRATICYTE®.

👉 https://proteocyte.com/straticyte/patients/

Canadian Dental Association Canadian Partnership Against Cancer Société de recherche sur le cancer / Cancer Research Society Fondation québécoise du cancer Manitoba Dental Association NB Dental Society Newfoundland and Labrador Dental Association

10/15/2026

Predict Risk. Guide Care. Improve Outcomes.

Oral cancer often develops from oral potentially malignant disorders, but identifying which lesions will progress remains a challenge.

STRATICYTE® combines biomarker analysis and digital pathology to provide objective, personalized insight into a patient’s 5-year oral cancer risk.

Because the future of oral cancer care is more than detection.
It’s prediction.

👉 Learn more: https://proteocyte.com/straticyte/

Alberta Dental Association Association des chirurgiens dentistes du Québec - ACDQ BC Cancer Foundation BC Dental Association CancerCare Manitoba Canadian Association of Oral and Maxillofacial Surgeons Canadian Cancer Society

10/08/2026

Go Beyond with STRATICYTE®.

Histopathology tells you what a lesion looks like.
STRATICYTE® provides additional insight into where it may be going.

Using biomarker analysis and advanced digital pathology, STRATICYTE® provides an objective, personalized 5-year OSCC risk score to supplement traditional histopathology.

✔️ Existing biopsy tissue
✔️ Objective risk stratification
✔️ Personalized 5-year risk assessment

Look Deeper. See Farther.

👉 https://proteocyte.com/straticyte/

Seattle Jaw Surgery Society of OMS Administrators SPOHNC Mouth Cancer Foundation Oral Health Foundation SurgeOn Events

10/06/2026

Know Your Risk. Know What Comes Next.

An oral lesion can raise questions.
STRATICYTE® helps provide answers.

Using your existing biopsy tissue, STRATICYTE® provides a personalized 5-year oral cancer risk score to help you and your healthcare provider make more informed decisions about your care.

For precision. For peace of mind.

👉 Learn more: https://proteocyte.com/straticyte/patients/

American Dental Association Beacon Oral & Maxillofacial Surgeons Everyday Oral Surgery Head and Neck Cancer Alliance Osteo Science Foundation Oral Cancer Foundation Paradigm Oral Health

09/29/2026

Improve OPMD Care & Outcomes

STRATICYTE’s® advanced digital pathology leverages biomarker analysis to go ‘beyond standard’ and help answer one of healthcare’s most important questions: Who is most at risk?

Go beyond standard, with STRATICYTE®

👉 https://proteocyte.com/

American Academy of Otolaryngology—Head and Neck Surgery American Academy of Oral Medicine American Academy of Oral and Maxillofacial Pathology - AAOMP American Association of Oral and Maxillofacial Surgeons - AAOMS American Cancer Society

09/22/2026

Go Beyond Pathology

Pathology can only tell you what a lesion is, but STRATICYTE® can tell you where it’s going.

STRATICYTE® dives deeper with biomarker analysis and cytomorphometrics for a personalized 5-year window to Oral Cancer Risk.

Look Deeper, See Farther – with STRATICYTE®: https://proteocyte.com/straticyte/

Nova Scotia Dental Association Ontario Dental Association Ontario Society of Oral and Maxillofacial Surgery The Terry Fox Foundation The Princess Margaret Cancer Foundation

Address

Toronto, ON
M5G1L7

Website

https://proteocyte.com/

Alerts

Be the first to know and let us send you an email when Proteocyte AI posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.